Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.57 |
| ▸ | TNF | P01375 | 3/20 | 0.55 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18689466 | 1.00 | TLR2 (0.57) | TLR2TNFSLC17A5KMT2AMDM4 | |
| SCHEMBL22636828 | 1.00 | TLR2 (0.57) | TLR2TNFSLC17A5KMT2AMDM4 | |
| SCHEMBL18708299 | 1.00 | TLR2 (0.57) | TLR2TNFSLC17A5KMT2AMDM4 | |
| SCHEMBL22636827 | 1.00 | TLR2 (0.57) | TLR2TNFSLC17A5KMT2AMDM4 | |
| SCHEMBL22636832 | 1.00 | TLR2 (0.57) | TLR2TNFSLC17A5KMT2AMDM4 | |
| SCHEMBL22636830 | 1.00 | TLR2 (0.57) | TLR2TNFSLC17A5KMT2AMDM4 | |
| SCHEMBL18689465 | 1.00 | TLR2 (0.57) | TLR2TNFSLC17A5KMT2AMDM4 | |
| SCHEMBL27252657 | 0.93 | TLR2 (0.49) | TLR2TNFSLC17A5KMT2A | |
| SCHEMBL31682400 | 0.93 | SLC17A5 (0.53) | TLR2TNFSLC17A5MDM4TP53 | |
| SCHEMBL20547534 | 0.91 | TNF (0.48) | TLR2TNFSLC17A5KMT2AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282827-A1 | LIPIDATED POLYMYXIN ANALOGUES | AUCKLAND UNISERVICES LTD (NZ) | 2025-09-11 | — | — | US | disclosed |
| EP-4384533-A1 | LIPIDATED POLYMYXIN ANALOGUES | Auckland Uniservices Limited (NZ) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017450-A1 | LIPIDATED POLYMYXIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282827-A1 | LIPIDATED POLYMYXIN ANALOGUES | PHOSPHO1, PCTP, PTMS | TLR2 31/4885TNF 599/4885SLC17A5 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.